Application of Ophiopogon japonicus dihydroisoflavones B in the preparation of drugs for the prevention and treatment of oligoasthenospermia
Ophiopogon japonicus dihydroisoflavones B are used to prepare drugs for the prevention and treatment of oligoasthenospermia. By improving DEHP-induced sperm damage, it solves the problem of poor efficacy of existing drugs and achieves significant therapeutic effects.
Patent Information
- Application Number
- CN202611550315.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-10-08
- Publication Date
- 2026-11-17
AI Technical Summary
Existing drugs for treating oligoasthenospermia have poor efficacy and significant side effects, making it urgent to find new and effective drugs.
Using Ophiopogon japonicus dihydroisoflavones B as the sole active ingredient, it is prepared into oral liquid, capsules or granules for the prevention and treatment of oligospermia and asthenospermia.
Ophiopogon japonicus dihydroisoflavones B significantly improved the reduction in sperm count, abnormal morphology, and motility dysfunction caused by DEHP, protected testicular function, and alleviated male oligoasthenospermia.
Smart Images

Figure CN123101518A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of drug preparation technology for the prevention and treatment of oligoasthenospermia, specifically involving the application of Ophiopogon japonicus dihydroisoflavones B in the preparation of drugs for the prevention and treatment of oligoasthenospermia. Background Technology
[0002] Oligospermia is defined as a sperm count of less than 39 × 10⁻⁶ in a single ejaculation after abstinence for 2 to 7 days. 6 sperm count / mL or sperm concentration less than 15 × 10⁶ 6 Oligospermia is a clinical condition characterized by a sperm count / mL of sperm, while semen volume, sperm motility, and the percentage of sperm with normal morphology are normal. Asthenospermia, on the other hand, is a clinical condition characterized by a sperm forward motility percentage of less than 32% in the semen, while other semen parameters are normal. Oligospermia and asthenospermia often occur simultaneously in clinical practice and are collectively referred to as oligoasthenospermia. The specific pathogenesis of oligoasthenospermia is not fully understood, and the causes are quite complex.
[0003] Currently, clinically used medications for treating oligospermia and asthenospermia include hormones, antioxidants, and aromatase inhibitors. Hormonal drugs, such as kallikrein and davidian pin, are suitable for asthenospermia complicated by mild varicocele and poor testicular microcirculation. However, hormone drugs have relatively weak efficacy and can irritate the gastrointestinal tract, easily causing bloating and diarrhea. Antioxidant drugs include levocarnitine, coenzyme Q10, zinc selenium, vitamin E / C, and glutathione. These drugs clear reactive oxygen species in the testes, reduce sperm membrane lipid peroxidation, improve sperm motility, and reduce the rate of sperm abnormalities. However, antioxidant drugs have limited effectiveness in improving severe oligospermia. Therefore, existing medications for treating oligospermia and asthenospermia have poor efficacy and significant side effects, necessitating the search for new drugs that can effectively treat asthenospermia. Summary of the Invention
[0004] To address the aforementioned technical problems, this invention provides the application of Ophiopogon japonicus dihydroisoflavones B in the preparation of drugs for the prevention and treatment of oligoasthenospermia.
[0005] To facilitate understanding of this invention, the materials used in this invention and their abbreviations are listed below: Ophiopogon japonicus dihydroisoflavones B, abbreviated as MO-B. Di(2-ethylhexyl) phthalate, abbreviated as DEHP. Reactive oxygen species, abbreviated as ROS. Sodium carboxymethyl cellulose, abbreviated as CMC. Oligospermia and asthenospermia, abbreviated as OAS.
[0006] The purpose of this invention is to provide the application of Ophiopogon japonicus dihydroisoflavones B in the preparation of drugs for the prevention and treatment of oligoasthenospermia, wherein the structural formula of Ophiopogon japonicus dihydroisoflavones B is as follows: .
[0007] Preferably, the drug uses Ophiopogon japonicus dihydroisoflavones B as its sole active ingredient.
[0008] Preferably, the content of Ophiopogon japonicus dihydroisoflavones B in the drug is 5 mg / mL to 10 mg / mL.
[0009] Preferably, the drug is prepared by adding pharmaceutically acceptable excipients or auxiliary ingredients, with Ophiopogon japonicus dihydroisoflavones B as the active ingredient.
[0010] Preferably, the excipients are selected from one or more of the following: excipients, diluents, lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, or preservatives.
[0011] Preferably, the diluent is a sodium carboxymethyl cellulose solution, a methanol solution, or an ethanol solution.
[0012] Preferably, the sodium carboxymethyl cellulose solution contains 0.9% to 1.1% sodium carboxymethyl cellulose by mass.
[0013] Preferably, the dosage form of the drug is any one of oral liquid, capsule, tablet or granule.
[0014] Compared with the prior art, the present invention has the following beneficial effects: This invention is the first to discover that MO-B can prevent the occurrence of oligoasthenospermia. The MO-B of this invention can improve hormonal secretion disorders induced by DEHP. MO-B can significantly improve DEHP-induced sperm count reduction, morphological abnormalities, and motility dysfunction in mice. MO-B treatment can effectively improve DEHP-induced seminiferous tubule structural disorders, loose arrangement of the seminiferous epithelial cell layer, significant reduction in the number of mature sperm in the lumen, and local vacuolation. Furthermore, the MO-B of this invention can significantly improve DEHP-induced blood-testis barrier leakage, increased ROS content in spermatogenic cells, and decreased expression of barrier-related proteins N-cadherin and ZO-1, secreted regulatory proteins AR and FSHR, and Sertoli cell marker protein SOX9. These results indicate that MO-B can improve Sertoli cell and spermatogenic cell damage. The MO-B of this invention alleviates DEHP-induced male oligoasthenospermia by inhibiting ROS production and thus improving Sertoli cell and spermatogenic cell damage. Therefore, MO-B has a significant protective effect against DEHP-induced testicular dysfunction and can be used to prevent the occurrence of oligoasthenospermia. Attached Figure Description
[0015] Figure 1 This is a graph showing the weight and testicular coefficient of the mouse testes in this invention. Where A represents testicular weight, and B represents the testicular coefficient.
[0016] Figure 2 This is a graph showing the testosterone content in the mouse testes of the present invention.
[0017] Figure 3This is a diagram showing sperm morphology and motility according to the present invention. Wherein, A represents sperm morphology; B represents sperm count; C represents sperm motility; D represents sperm abnormality rate; E represents the percentage of sperm with first-order motility; and F represents the percentage of sperm with fourth-order motility.
[0018] Figure 4 This is a HE staining image of the testis group in this invention.
[0019] Figure 5 This is a diagram showing the leakage of biotin into the blood-testis barrier according to the present invention.
[0020] Figure 6 This is a ROS fluorescence image of the testis according to the present invention. In the image, A represents the ROS fluorescence staining result in the testis, and B represents the ROS fluorescence intensity in the testis.
[0021] Figure 7 This diagram shows the expression and quantification of N-cadherin, ZO-1, AR, FSHR, and SOX9 in testicular tissue according to the present invention. In the diagram, A represents expression, and B represents quantification. Detailed Implementation
[0022] To enable those skilled in the art to better understand and implement the technical solutions of the present invention, the following detailed description, in conjunction with preferred embodiments and accompanying drawings, provides a clear and complete account of the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, and not all of them. All other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are within the scope of protection of the present invention.
[0023] It should be noted that all technical terms used in this invention are for the purpose of describing specific embodiments only and are not intended to limit the scope of protection of this invention. Unless otherwise specified, all raw materials, reagents, instruments and equipment used in the following embodiments of this invention can be purchased from the market or prepared by existing methods.
[0024] The materials used in this invention mainly include an enzyme-linked immunosorbent assay (ELISA) kit for testosterone (T), EZ-Link™ Sulfo-NHS-LC-Biotin tracer, Streptavidin-Fitc, anti-fluorescence quenching mounting medium, and an enhanced chemiluminescent protein blot detection kit.
[0025] The following reagents were used: Enzyme-linked immunosorbent assay (ELISA) kit for testosterone (T), purchased from Shanghai Enzyme-Link Biotechnology Co., Ltd. (model number ml001948); EZ-Link™ Sulfo-NHS-LC-Biotin tracer, purchased from Thermo Fisher Scientific (model number 21335); Streptavidin-Fitc, purchased from Merck AG, Darmstadt, Germany (model number S3762); Anti-fluorescence quenching mounting medium, purchased from Beyotime Biotechnology Co., Ltd. (model number P0131); and Enhanced chemiluminescent protein blot assay kit, purchased from Jiangsu KGI Biotechnology Co., Ltd. (model number KGF6103-100).
[0026] The mice used in this invention were 5-week-old inbred, specific pathogen-free, SPF-grade healthy male C57BL / 6 mice, weighing 18g-22g, purchased from the Experimental Animal Center of Ningxia Medical University. All mice were acclimatized for one week in cages at 22°C with a 12-hour light / dark cycle before use.
[0027] All treatment and animal care procedures in this invention comply with ethical principles of animal use and care and have been approved by the Medical Ethics Committee of Ningxia Medical University.
[0028] DEHP is the most widely used and studied plasticizer, and it has been shown to cause testicular hypoplasia syndrome, cancer, and male fertility disorders, and is significantly associated with decreased male hormone levels, sperm count, and semen quality. Therefore, this invention uses DEHP to establish a mouse model of oligoasthenospermia.
[0029] Example 1 The application of Ophiopogon japonicus dihydroisoflavones B in the preparation of drugs for the prevention and treatment of oligoasthenospermia includes the following steps: Dissolve 0.015 g of MO-B in 3 mL of 1% CMC solution to obtain a drug for the prevention and treatment of oligoasthenospermia, denoted as MO-B(L). Dissolve 0.15 g of DEHP in 3 mL of corn oil to obtain a DEHP solution.
[0030] Ten mice were randomly selected and administered MO-B at a dose of 25 mg / kg / day per kilogram of body weight via gavage for 7 consecutive days. Then, the mice were cultured for 35 days by gavage with DEHP at a dose of 250 mg / kg / day per kilogram of body weight and MO-B at a dose of 25 mg / kg / day per kilogram of body weight, resulting in mice denoted as DEHP+MO-B(L). During this period, the mice were allowed free access to food and water daily, and their body weight was monitored.
[0031] Example 2 The application of Ophiopogon japonicus dihydroisoflavones B in the preparation of drugs for the prevention and treatment of oligoasthenospermia includes the following steps: Dissolve 0.030 g of MO-B in 3 mL of 1% CMC solution to obtain a drug for the prevention and treatment of oligoasthenospermia, denoted as MO-B(H). Dissolve 0.15 g of DEHP in 3 mL of corn oil to obtain a DEHP solution.
[0032] Ten mice were randomly selected and administered 50 mg of MO-B per kilogram of body weight daily by gavage for 7 consecutive days. Then, the mice were cultured for 35 days by gavage with 250 mg of DEHP and 50 mg of MO-B per kilogram of body weight daily. The resulting mice were designated DEHP+MO-B(H). During this period, the mice were allowed free access to food and water daily, and their body weight was dynamically monitored.
[0033] Comparative Example 1 The application of Ophiopogon japonicus dihydroisoflavones B in the preparation of drugs for the prevention and treatment of oligoasthenospermia includes the following steps: Ten mice were randomly selected and administered 0.1 mL of 1% CMC solution per kilogram of body weight daily by gavage for 7 consecutive days. Then, the mice were cultured for 35 consecutive days by gavage with 0.1 mL of 1% CMC solution and 0.1 mL of corn oil per kilogram of body weight. The resulting mice were designated CON. During this period, the mice were allowed free access to food and water daily, and their body weight was dynamically monitored. The dosage was adjusted dynamically based on changes in body weight.
[0034] Comparative Example 2 The application of Ophiopogon japonicus dihydroisoflavones B in the preparation of drugs for the prevention and treatment of oligoasthenospermia includes the following steps: Dissolve 0.15g of DEHP in 3mL of corn oil to obtain a DEHP solution.
[0035] Ten mice were randomly selected and administered 0.1 mL of 1% CMC solution per kilogram of body weight by gavage daily for 7 consecutive days. Then, the mice were cultured for 35 days by gavage with 250 mg of DEHP and 0.1 mL of 1% CMC solution per kilogram of body weight. The resulting mice were designated DEHP mice. During this period, the mice were allowed free access to food and water, and their body weight was dynamically monitored.
[0036] Comparative Example 3 The application of Ophiopogon japonicus dihydroisoflavones B in the preparation of drugs for the prevention and treatment of oligoasthenospermia includes the following steps: Dissolve 0.030 g of MO-B in 3 mL of 1% CMC solution to obtain a drug for the prevention and treatment of oligoasthenospermia. Dissolve 0.15 g of DEHP in 3 mL of corn oil to obtain a DEHP solution.
[0037] Ten mice were randomly selected and administered 0.1 mL of 1% CMC solution per kilogram of body weight by gavage daily for 7 consecutive days. Then, the mice were cultured for 35 days by gavage with 50 mg of MO-B and 0.1 mL of 1% CMC solution per kilogram of body weight. The resulting mice were designated MO-B. During this period, the mice were allowed free access to food and water daily, and their body weight was dynamically monitored.
[0038] To illustrate the beneficial effects of the present invention, the following experiments were conducted on mice cultured in Examples 1-2 and Comparative Examples 1-3.
[0039] Mice cultured in Examples 1-2 and Comparative Examples 1-3 were euthanized, and the bilateral testes and epididymis were separated using surgical instruments. Excess surrounding adipose tissue was removed to obtain the testes and epididymis.
[0040] The organ coefficient of the testis is obtained by calculating the ratio of the weight of the testis and epididymis to the body weight.
[0041] 1. Sperm quality assessment The mouse epididymal tissue was thoroughly rinsed three times with 0.9% physiological saline at 4°C to remove impurities that might affect sperm observation. The epididymal tissue was then transferred to a sterile centrifuge tube containing 1.0 mL of physiological saline at 37°C, and incubated at 37°C for 10 min to form a sperm suspension. The sperm suspension was then transferred and filtered through a 200-mesh sieve into another 1.5 mL sterile centrifuge tube. 10 μL of the filtered sperm suspension was then added to the counting chamber of a sperm counting chamber. Sperm morphology was observed using an inverted phase-contrast microscope, and sperm density and motility parameters were analyzed using the SAS Medical animal semen analysis system. Three fields of view were randomly selected from each semen sample for analysis.
[0042] 2. Morphological analysis of the testis Mouse testes were initially fixed for 12 hours with a 4% paraformaldehyde solution (pH 7.4). Then, using a microdissecting needle, multiple punctures were made in the testicular capsule at 6 wells per sample for secondary fixation, with a total fixation time of 24 hours. After rinsing with running water for 12 hours, the tissue was dehydrated by soaking in 70% ethanol for 2 hours, 80% ethanol for 1.5 hours, 90% ethanol for 1 hour, 95% ethanol for 1 hour, anhydrous ethanol I for 20 minutes, and anhydrous ethanol II for 20 minutes. Clearing was then performed by soaking in xylene I for 15 minutes and xylene II for 15 minutes. After dehydration and clearing, the tissue sections were mounted with neutral resin and the morphology of the testes was observed and photographed under an optical microscope. The sections were then embedded in paraffin wax I and II for 1 hour each. 5 μm thick tissue sections were prepared using a paraffin microtome, and after baking and hydration with graded ethanol solutions, hematoxylin and eosin staining was performed.
[0043] 3. Serum biochemical analysis Blood was collected from the abdominal aorta of mice and allowed to coagulate at 4°C for 1 hour. The blood sample was then centrifuged at 3000 rpm for 15 min at 4°C to obtain serum. Serum testosterone levels were determined using an enzyme-linked immunosorbent assay (ELISA) kit, following the kit's instructions. The structural integrity of the biotin-avidin system was detected using the biotin-avidin system. The levels of reactive oxygen species (ROS) in spermatogenic cells were detected using DHE fluorescence staining.
[0044] 4. Biotin tracer method EZ-Link™ Sulfo-NHS-LC-Biotin tracer was dissolved in PBS containing 10 mg / mL calcium chloride at pH 7.1 to prepare a working solution of 0.1 mg / mL. Mice with DEHP+MO-B (L), DEHP+MO-B (H), CON, DEHP, and MO-B were anesthetized with sodium pentobarbital. A small incision was made in the abdominal cavity, and the testis was gently removed. 50 μL of the working solution was injected subtunically into the tunica albuginea of the testis using a glass needle. After injection, the testis was gently returned to the abdominal cavity, and the skin wound was sutured. The mice were kept alive at a constant temperature of 37°C for 30 minutes. After 30 minutes, the mice were anesthetized and euthanized. The testis was then quickly placed in liquid nitrogen and prepared into 5 μm frozen sections as soon as possible. After sectioning, the sections were fixed with 4% paraformaldehyde for 10 min, then permeabilized with 0.2% Triton-100 membrane for 10 min, followed by washing three times with PBST for 5 min each time. After washing, the sections were blocked with 5% fetal bovine serum for 1 h, and then incubated with Streptavidin-Fitc for 1 h. The sections were washed three times with PBST for 5 min each time. Finally, after mounting with anti-fluorescence quenching mounting medium containing DAPI, the frozen sections of the testis were photographed using an upright fluorescence microscope.
[0045] 5. Immunohistochemistry After dewaxing and graded-distillation with alcohol, antigen extraction was performed using 0.01 mol / L sodium citrate buffer. The sections were then treated with 3% hydrogen peroxide for 20 min to inhibit endogenous peroxidase activity. Next, the sections were blocked with 10% BSA at room temperature for 1 h. After overnight incubation with a specific primary antibody at 4 °C, the sections were incubated with HRP-linked secondary antibody at 37 °C for 1 h. After washing with PBS, the sections were developed with DAB and then stained with hematoxylin. Finally, images were captured using a digital scanning microscope. Results were evaluated using ImageJ software 8.0.
[0046] 6. Ethidium dihydrostaining Freshly obtained testicular tissue was initially fixed for 12 hours with a 4% paraformaldehyde solution at pH 7.4. Then, eight wells per sample were punctured in the testicular capsule using a microdissecting needle for secondary fixation, with a total fixation time of 24 hours. The tissue was then rinsed with running water for 12 hours, dehydrated with 30% sucrose solution, and rapidly frozen in embedding medium. Tissue sections with a thickness of 20 μm were prepared using a cryostat. The tissue sections were then incubated with 10 μM DHE working solution at 37°C in the dark for 30 minutes. After incubation, the sections were gently washed three times with PBS at 37°C to remove unbound probes. Finally, the sections were mounted with DAPI-containing mounting medium and immediately observed under a fluorescence microscope.
[0047] 7. Protein immunoblotting RT-PCR and Western blotting were used to detect the expression of key hormone synthesis enzyme genes and proteins Star, Cyp11a1, Cyp17a1, Cyp19a1, Hsd17b1, Hsd17b7, Vasa, and Dazl in testicular tissue. Testicular tissue was incubated with lysis buffer containing protease inhibitors on ice for 30 minutes to obtain a tissue protein mixture. The sample was then centrifuged at 12000 rpm for 15 minutes at 4°C to obtain the supernatant. The total protein concentration of the sample was determined using a BCA protein assay kit. After boiling the protein sample for 10 minutes, 40 μg of protein sample was added to each lane of a 12.5% sodium dodecyl sulfate-polyacrylamide gel for electrophoresis. The protein was then transferred to a polyvinylidene fluoride (PVDF) membrane. The PVDF membrane was blocked with 5% skim milk powder. After washing with PBST, the membrane-specific primary antibody was incubated overnight at 4°C on a shaker. After washing three times with PBST, the protein expression signal was incubated with the secondary antibody at room temperature for 2 hours. Finally, the protein expression signal was visualized using an enhanced chemiluminescent blot assay kit and a ChemiDocMP imaging system.
[0048] 8. Experimental Results The weight and testicular coefficient of the mouse testes of this invention are as follows: Figure 1 As shown in the figure. ns indicates no significant difference, * indicates P < 0.05, and ** indicates P < 0.01. The results show that MO-B can improve the decrease in testicular weight and testicular coefficient caused by DEHP exposure.
[0049] The testosterone content in the mouse testes of this invention is as follows: Figure 2 As shown in the figure. The results indicate that MO-B can improve the decrease in testosterone levels caused by DEHP exposure.
[0050] The sperm morphology and motility of the present invention are as follows: Figure 3 As shown in the figure. The results showed that MO-B could improve the decrease in sperm count, decrease in sperm motility, increase in sperm abnormality rate, and decrease in sperm grade 1 and 4 motility caused by DEHP exposure.
[0051] The morphological pathology of the testis group of this invention, as shown by HE staining. Figure 4 As shown in the figure. The results showed that MO-B improved the loss and loose arrangement of spermatogenic cells caused by DEHP, reduced the number of mature sperm, and caused testicular cavitation and Sertoli cell vacuolation.
[0052] The biotin-blood-testis barrier leakage of the present invention, such as Figure 5 As shown in the figure. The results show that MO-B treatment significantly improved BTB leakage caused by DEHP.
[0053] The ROS fluorescence image in the testes of this invention is shown below. Figure 6 As shown in the figure. The results showed that MO-B treatment significantly improved the ROS content in spermatogenic cells increased by DEHP.
[0054] The expression and quantification of N-cadherin, ZO-1, AR, FSHR, and SOX9 in testicular tissue of the present invention are shown in the figure below. Figure 7 As shown in the figure. The results showed that MO-B treatment significantly improved the DEHP-induced decrease in the expression of barrier-related proteins N-cadherin and ZO-1, secretion regulatory proteins AR and FSHR, and supporting cell marker protein SOX9.
[0055] Sertoli cells and their tight junctions form the basis of the barrier cell barrier (BTB), and BTB damage is considered a significant pathological process leading to decreased sperm quality. Using biotin as a tracer, we found that MO-B treatment significantly improved BTB leakage caused by DEHP. Furthermore, we found that MO-B treatment significantly improved the ROS levels in spermatogenic cells increased by DEHP. Western blot results also showed that MO-B treatment significantly improved the DEHP-induced decrease in the expression of barrier-related proteins N-cadherin and ZO-1, secretory regulatory proteins, and the Sertoli cell marker protein SOX9. These studies indicate that MO-B improves damage to Sertoli cells and spermatogenic cells. This suggests that MO-B may improve damage to Sertoli cells and spermatogenic cells by inhibiting ROS production, thereby alleviating DEHP-induced oligoasthenospermia in men.
[0056] Oxidative stress is one of the core pathological mechanisms leading to OAS (Oligospermia ulcera). When excessive ROS (reactive oxygen species) is produced in the body or seminal plasma, exceeding the body's antioxidant system's clearance capacity, it disrupts the integrity of the blood-testis barrier, leading to immune microenvironment dysregulation, inducing massive apoptosis of spermatogenic cells, and reducing the number of mature sperm. It also induces reduced testosterone production in interstitial cells, disrupts the pituitary-gonadal axis's spermatogenic regulation, and hinders the proliferation and differentiation of the seminiferous epithelium. Furthermore, it induces dysfunction in Sertoli cells in supplying nutrients to spermatogenic cells, providing structural support, and maintaining the immune barrier, thus impairing spermatogenesis. In addition, sperm mitochondria are the energy supply center and the main site of ROS production; oxidative imbalance directly destroys the sperm motility system. Sperm cell membranes are rich in polyunsaturated fatty acids and are highly sensitive to ROS, easily undergoing lipid peroxidation. After sperm maturation, the cytoplasm is extremely sparse, and the sperm itself has almost no endogenous antioxidant enzymes, relying entirely on the antioxidant system in the seminal plasma to resist ROS. Therefore, excessive ROS can also lead to impaired mitochondrial electron transport chain function, insufficient ATP synthesis, and decreased cell membrane fluidity, resulting in asthenospermia. The MO-B of this invention alleviates DEHP-induced oligoasthenospermia by inhibiting ROS production and thereby improving damage to supporting cells and spermatogenic cells.
[0057] It should be noted that when numerical ranges are involved in this invention, it should be understood that both endpoints of each numerical range and any value between the two endpoints can be selected. Since the steps and methods used are the same as in the embodiments, preferred embodiments are described in this invention to avoid redundancy. Although preferred embodiments of this invention have been described, those skilled in the art, once they understand the inventive concept of this invention, can make other changes and modifications to these embodiments, and all such changes and modifications fall within the scope of this invention.
[0058] Obviously, those skilled in the art can make various modifications and variations to this invention without departing from its spirit and scope. If such modifications and variations fall within the scope of equivalents of this invention, then this invention is also intended to include such modifications and variations.
Claims
1. The application of Ophiopogon japonicus dihydroisoflavones B in the preparation of drugs for the prevention and treatment of oligoasthenospermia, characterized in that, The structural formula of the Ophiopogon japonicus dihydroisoflavones B is as follows: .
2. The application of the Ophiopogon japonicus dihydroisoflavones B according to claim 1 in the preparation of drugs for the prevention and treatment of oligoasthenospermia, characterized in that, The drug uses Ophiopogon japonicus dihydroisoflavones B as its sole active ingredient.
3. The application of the Ophiopogon japonicus dihydroisoflavones B according to claim 2 in the preparation of drugs for the prevention and treatment of oligoasthenospermia, characterized in that, The content of Ophiopogon dihydroisoflavones B in the drug is 5 mg / mL to 10 mg / mL.
4. The application of the Ophiopogon japonicus dihydroisoflavones B according to claim 1 in the preparation of drugs for the prevention and treatment of oligoasthenospermia, characterized in that, The drug is prepared with Ophiopogon japonicus dihydroisoflavones B as the active ingredient and pharmaceutically acceptable excipients or auxiliary ingredients added.
5. The application of the Ophiopogon japonicus dihydroisoflavones B according to claim 4 in the preparation of drugs for the prevention and treatment of oligoasthenospermia, characterized in that, The excipients are selected from any one or more of the following: excipients, diluents, lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, or preservatives.
6. The application of the Ophiopogon japonicus dihydroisoflavones B according to claim 5 in the preparation of drugs for the prevention and treatment of oligoasthenospermia, characterized in that, The diluent is a sodium carboxymethyl cellulose solution, a methanol solution, or an ethanol solution.
7. The application of the Ophiopogon japonicus dihydroisoflavones B according to claim 6 in the preparation of drugs for the prevention and treatment of oligoasthenospermia, characterized in that, The sodium carboxymethyl cellulose solution contains 0.9% to 1.1% sodium carboxymethyl cellulose by mass.
8. The application of the Ophiopogon japonicus dihydroisoflavones B according to claim 4 in the preparation of drugs for the prevention and treatment of oligoasthenospermia, characterized in that, The dosage form of the drug is any one of oral liquid, capsule, tablet or granule.
